(Q40006328)

16 September 2017

Entecavir exhibits inhibitory activity against human immunodeficiency virus under conditions of reduced viral challenge (English)

1 reference

16 September 2017

1 reference

Pin-Fang Lin

1

1 reference

16 September 2017

Beata Nowicka-Sans

2

1 reference

16 September 2017

Brian Terry

3

1 reference

16 September 2017

Sharon Zhang

4

1 reference

16 September 2017

Chunfu Wang

5

1 reference

16 September 2017

Li Fan

6

1 reference

16 September 2017

Ira Dicker

7

1 reference

16 September 2017

Volodymyr Gali

8

1 reference

16 September 2017

Helen Higley

9

1 reference

16 September 2017

Neil Parkin

10

1 reference

16 September 2017

Daniel Tenney

11

1 reference

16 September 2017

Mark Krystal

12

1 reference

16 September 2017

Richard Colonno

13

1 reference

16 September 2017

language of work or name

English

0 references

publication date

3 March 2008

1 reference

Antimicrobial Agents and Chemotherapy

16 September 2017

1 reference

16 September 2017

52

1 reference

16 September 2017

5

1 reference

16 September 2017

1759-1767

1 reference

The HBV drug entecavir - effects on HIV-1 replication and resistance

16 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346618

Regulation of Toll-like receptor-2 expression in chronic hepatitis B by the precore protein

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346618

An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346618

Antiretroviral therapy for hepatitis B virus-HIV-coinfected patients: promises and pitfalls

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346618

Challenges for the clinical development of new nucleoside reverse transcriptase inhibitors for HIV infection.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346618

Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346618

Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346618

HBV X protein targets HIV Tat-binding protein 1.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346618

Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC).

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346618

Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346618

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346618

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346618

High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346618

Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346618

Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase.

22 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346618

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346618

Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346618

Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B

20 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2346618

Management of chronic hepatitis B and C in HIV-coinfected patients

2 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18316521

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Antiviral options for the treatment of chronic hepatitis B

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18316521

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/18316521

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.01313-07

1 reference

16 September 2017

1 reference

16 September 2017

1 reference